Genmab A/S ADR (GMAB)

$29.98 0.33 (1.11%)

16:00 EDT GMAB Stock Quote Delayed 30 Minutes

GMAB Stock Earnings: Genmab Beats EPS, Beats Revenue for Q1 2024

By InvestorPlace Earnings May 2, 2024

GMAB stock results show that Genmab beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

7 Must-Buy Stocks That Are on Ridiculous Discount Now

7 Underappreciated Biotech Stocks to Pick Up on the Cheap

3 Biotech Stocks You Better Be Buying on Each and Every Dip

More Articles

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 375,160

Day's Range $29.52 - $30.

52-Week Range $26.32 - $42.72

Dividend & Yield N/A (N/A)

GMAB Stock Predictions, Articles, and Genmab A/S ADR News

From InvestorPlace
From the Web

3 Biotech Stocks That AI is Loving in July

By Gabriel Osorio-Mazzilli, InvestorPlace Contributor Jul 12, 2023

As AI becomes a more entrenched aspect of society, investors can lean on these AI recommended biotech stocks with predicted high potential.

3 Biotech Companies to Watch in 2023

By Muslim Farooque, InvestorPlace Contributor Jan 6, 2023

These biotech companies to watch are remarkably strong businesses that offer healthy upside potential as we head into a new year.

Our 7 Top Biotech Stock Picks for 2023

By Josh Enomoto, InvestorPlace Contributor Dec 9, 2022

Following the devastation of Covid-19, there’s greater interest toward medical innovations, thus bolstering biotech stock picks for 2023.

7 Top-Rated Stocks to Buy for a More Powerful Portfolio

By Louis Navellier, Editor, Growth Investor Jan 21, 2020

The market is hot, but that’s no reason to forgo quality when picking the top stocks to buy now. Here are seven that stand out from the rest.

10 Great Biotech Stocks to Buy in Q4

By Sarah Smith, Editor-in-Chief, InvestorPlace.com Oct 7, 2019

With FDA Breakthrough Therapy designations and robust drug pipelines, these biotech companies are all stocks to buy for 2020.

NASDAQ:GMAB is showing good growth, while it is not too expensive.

From Chartmill May 2, 2024

Investors seeking growth at a reasonable cost should explore GENMAB A/S -SP ADR (NASDAQ:GMAB).

Is NASDAQ:GMAB on the Verge of a Major Breakout as a Strong Growth Stock?

From Chartmill Mar 28, 2024

Exploring the Growth Potential of GENMAB A/S -SP ADR (NASDAQ:GMAB) as It Nears a Breakout.

NASDAQ:GMAB is showing good growth, while it is not too expensive.

From Chartmill Mar 21, 2024

For those who appreciate growth without the sticker shock, GENMAB A/S -SP ADR (NASDAQ:GMAB) is worth considering.

Why NASDAQ:GMAB Is a Promising High-Growth Stock in the Midst of Consolidation.

From Chartmill Mar 5, 2024

Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation.

NASDAQ:GMAB is showing good growth, while it is not too expensive.

From Chartmill Feb 29, 2024

While growth is established for GENMAB A/S -SP ADR (NASDAQ:GMAB), the stock's valuation remains reasonable.

NASDAQ:GMAB, a strong growth stock, setting up for a breakout.

From Chartmill Feb 8, 2024

Is GENMAB A/S -SP ADR (NASDAQ:GMAB) on the Verge of a Major Breakout as a Strong Growth Stock?

ADVERTISEMENT